Cempra Inc. (NASDAQ:CEMP)’s share price fell 2.4% during trading on Monday . The company traded as low as $17.92 and last traded at $18.02, with a volume of 321,759 shares traded. The stock had previously closed at $18.47.

A number of research firms have commented on CEMP. Jefferies Group reaffirmed a “buy” rating on shares of Cempra in a report on Sunday, May 29th. WBB Securities reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Cempra in a report on Monday, May 2nd. Zacks Investment Research downgraded shares of Cempra from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Leerink Swann reaffirmed a “hold” rating on shares of Cempra in a report on Monday, May 2nd. Finally, Cowen and Company reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Cempra in a report on Thursday, April 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. Cempra presently has an average rating of “Buy” and a consensus price target of $36.27.

The company’s market cap is $874.83 million. The stock’s 50 day moving average price is $18.22 and its 200-day moving average price is $18.17.

Cempra (NASDAQ:CEMP) last posted its earnings results on Monday, May 2nd. The company reported ($0.61) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.02. The company earned $2.70 million during the quarter, compared to analyst estimates of $3.94 million. The firm’s revenue for the quarter was down 80.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.41) earnings per share. On average, equities analysts anticipate that Cempra Inc. will post ($2.58) EPS for the current fiscal year.

A number of large investors recently bought and sold shares of the company. ProShare Advisors LLC raised its stake in Cempra by 9.6% in the fourth quarter. ProShare Advisors LLC now owns 39,993 shares of the company’s stock valued at $1,245,000 after buying an additional 3,490 shares during the period. South Dakota Investment Council raised its position in shares of Cempra by 7.3% in the fourth quarter. South Dakota Investment Council now owns 140,700 shares of the company’s stock worth $4,380,000 after buying an additional 9,600 shares during the period. Gabelli Funds LLC raised its position in shares of Cempra by 19.7% in the fourth quarter. Gabelli Funds LLC now owns 93,509 shares of the company’s stock worth $2,911,000 after buying an additional 15,409 shares during the period. Wells Fargo & Company MN raised its position in shares of Cempra by 14.2% in the fourth quarter. Wells Fargo & Company MN now owns 307,113 shares of the company’s stock worth $9,561,000 after buying an additional 38,204 shares during the period. Finally, California Public Employees Retirement System raised its position in shares of Cempra by 427.9% in the fourth quarter. California Public Employees Retirement System now owns 117,200 shares of the company’s stock worth $3,648,000 after buying an additional 95,000 shares during the period.

Cempra Inc is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company’s lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.